Telatinib

特拉替尼

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameTelatinib

Drug Alias NameTelatinibum叶枯酞甲磺酸特拉替尼Telatinib mesylate替拉替尼 +[7]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 2 antagonistsStem cell growth factor receptor inhibitors +[4]

TargetsStem cell growth factor receptorVascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[4]

Therapy Area/IndicationsSolid tumoursStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSpainMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBayer AG

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEddingpharm Bv Yiteng Pharmaceutical(Thaizhou) Co Ltd

Inactive CompaniesAct Biotech Inc

Active IndicationsStomach Neoplasms

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A